JUNS — Jupiter Neurosciences Inc
NASDAQ · Pharmaceuticals · Pharmaceuticals
- Latest Close
- $0.39
- 30-Day Move
- -65.5%
- Market Cap
- $13M
- Shares Outstanding
- 34,430,000
- P/B Ratio
- 84.9
- ROE
- -58.5%
Analyst consensus: Buy · 7 analysts
Jupiter Neurosciences Inc
A read-only Alphactor snapshot forJupiter Neurosciences Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-24
Topline snapshot
Latest Close
$0.39
30-Day Move
-65.5%
Market Cap
$13M
Shares Outstanding
34,430,000
P/B Ratio
84.9
ROE
-58.5%
$0.39
-65.5%last 90 delayed daily bars
90D High
$1.20
90D Low
$0.31
Avg Volume
251,873
Net margin is -165.8%, useful for comparing JUNS against peers in Pharmaceuticals.
JUNS is down 65.5% over the last 30 trading days shown on this page.
Latest operating income is $-3M, which helps anchor the headline ratios with an actual earnings figure.
Latest Close
$0.39
30-Day Move
-65.5%
Market Cap
$13M
Shares Outstanding
34,430,000
P/B Ratio
84.9
ROE
-58.5%
ROA
-39.3%
Operating Margin
-161.4%
Net Margin
-165.8%
Debt / Equity
0.04
Current Ratio
2.31
Latest Revenue
$21,796
Revenue
$21,796
Gross Profit
--
Operating Income
$-3M
Net Income
$-3M
Gross Margin
--
Net Margin
-16582.6%
Current Ratio
2.31
Debt / Equity
0.04
Altman Z
-13.53
Distress
Piotroski
2
Weak (0-3)
Cash Conversion
0.63x
Rule of 40
--
Insufficient data
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $233,281 | $-3M | $-5M | $-1M |
| 2023-12-31 | $0 | $-4M | $-5M | $-480,953 |
| 2024-12-31 | $0 | $-3M | $-2M | $-4M |
| 2025-12-31 | $21,796 | $-9M | $-9M | $-5M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
Buy Value
$14,280.42
Sell Value
$0
Buys
21
Sells
0
Buy Value
$14,280.42
Sell Value
$0
Buy/Sell Ratio
21.00x
After signup
The full app goes deeper on insider behavior
Inspect longer insider history, recurring buyers and sellers, and the broader transaction context beyond this snapshot.
Continue into deeper institutional and alternative-data views once you sign up.
| Date | Name | Type | Shares | Price |
|---|---|---|---|---|
| 2025-07-02 | Elmasri Saleem | A | 102,128 | $0.00 |
| 2025-07-02 | Silva Alison D. | A | 255,320 | $0.00 |
| 2025-07-01 | Silva Alison D. | Buy | 250 | $1.03 |
| 2025-07-01 | Silva Alison D. | Buy | 250 | $1.03 |
| 2025-07-01 | Silva Alison D. | Buy | 250 | $1.03 |
| 2025-07-01 | ROSEN CHRISTER | Buy | 3,100 | $1.02 |
| 2025-07-01 | ROSEN CHRISTER | Buy | 500 | $1.01 |
| 2025-06-30 | Silva Alison D. | Buy | 100 | $1.05 |
| ETF | Shares | Weight | As Of |
|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 128,042 | 0.00% | 2025-12-31 |
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 77,674 | 0.00% | 2026-02-28 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 33,100 | 0.00% | 2025-12-31 |
| Fidelity Concord Street Trust-Fidelity Series Total Market Index Fund | 17,979 | 0.00% | 2026-02-28 |
| Fidelity Concord Street Trust-Fidelity Total Market Index Fund | 16,075 | 0.00% | 2026-02-28 |
| Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund | 15,860 | 0.00% | 2026-02-28 |
After signup
The deeper ownership view shows who is leaning in
Open richer institutional and holder diffs to see position changes across filings instead of one static snapshot.
Use those ownership shifts alongside conviction and alerts in the full app workflow.
Qube Research & Technologies
Filed 2025-08-14
--
--
Vanguard Group
Filed 2025-11-07
$379,863
--
Geode Capital Management
Filed 2025-11-12
$182,714
--
Northern Trust
Filed 2025-11-14
$43,681
--
4.14
Consensus
Buy—
—
—
7
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.